US › Healthcare

Context Therapeutics Inc (CNTX)

US · Healthcare · Biotechnology

$0.62+2.93%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-8.7M

Profit YoY

-89.6%

EPS

$-0.09

EPS estimate

$-0.12

EPS came in at -0.09 against a street estimate of -0.12 — a beat of 25.0%.

Key statistics

Market cap

$55.1M

Forward P/E

0.0

P/B

1.05

Book value

$0.57

EPS (TTM)

$-0.42

52-week high

$3.62

52-week low

$0.55

50-day MA

$1.15

200-day MA

$1.73

Beta

1.75

Analyst view

Analysts rate Context Therapeutics Inc a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $5.38.

Shareholding

Insiders

1.35%

Institutions

82.47%

Largest institutional holders

Fund	Stake
MPM Oncology Impact Management LP	11.62%
Avidity Partners Management LP	10.88%
Deep Track Capital, LP	8.08%
Nextech Invest, Ltd.	8.08%
Soleus Capital Management, L.P.	7.58%
Octagon Capital Advisors LP	5.71%
Blue Owl Capital Holdings LP	5.54%
Franklin Resources Inc	4.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Context Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.